أفضل بودكاسات Ccrm (2024)

1
Biomanufacturing redefined: The role of AI and robotics in producing cell and gene therapies 34:59

9d ago34:59

34:59

Featuring: Christopher P. Boone, PhD, Group Vice President, Research Services, Health & Life Sciences, Oracle Kenneth L. Harris, Chief Strategy Officer and Head of AI, OmniaBio Inc. *** We are excited to share the first episode in the fourth season (!) of Commercializing Living Therapies with CCRM. A big thanks to all our listeners. In this episode…

1
Expert insights for taking a cell or gene therapy company from vision to reality 26:25

8M ago26:25

26:25

Featuring: Jacki Jenuth, PhD, Partner and COO, Lumira Ventures Robin Quirk, PhD MBA, Vice President, Technology Sourcing and Venture Development, CCRM *** In this episode, we explore the dynamics of venture capital (VC) and company creation with Jacki Jenuth, Partner and COO, Lumira Ventures, and Robin Quirk, Vice President, Technology Sourcing and…

1
Regulators' strategies for managing the surge in cell and gene therapies 27:35

10M ago27:35

27:35

Featuring: Michael Rosu-Myles, PhD, Executive Director, Health Canada Josephine Lembong, PhD, Senior Manager, Science and Industry Affairs, Alliance for Regenerative Medicine *** Currently, there are more than 2,000 cell and gene therapies in clinical trials worldwide. With a goal of ensuring that safe and quality products are approved for use by p…

1
How Creative Destruction Lab accelerates the advanced therapies industry 24:23

11M ago24:23

24:23

Featuring: Sonia Sennik, Executive Director, Creative Destruction Lab Glenn MacLean, Director, Technology Sourcing and Venture Development, CCRM *** In many science-oriented fields, including regenerative medicine and advanced therapies, researchers and company founders often require additional support and expertise to successfully commercialize th…

1
The synergy solution: How public-private partnerships advance regenerative medicine 34:43

1y ago34:43

34:43

Featuring: Matthew Durdy, Chief Executive Officer, Cell and Gene Therapy Catapult Michael May, PhD, President and Chief Executive Officer, CCRM *** Public-private partnerships are collaborations between government agencies and private-sector companies. In this interview, Matthew Durdy, CEO, Cell and Gene Therapy Catapult, and Michael May, President…

1
Catalysts of change: Canada’s research hubs are shaping the future of biomanufacturing 33:24

1y ago33:24

33:24

Featuring: Matthew Miller, B.M.Sc., PhD, Director, Michael G. DeGroote Institute for Infectious Disease Research; Co-Director, Canadian Pandemic Preparedness Hub (CP2H), McMaster University Patrycja Thompson, PhD, Director, Strategy & Operations, the Canadian Hub for Health Intelligence & Innovation in Infectious Diseases (HI3), University of Toron…

1
From code to cure: Exploring the synergies of artificial intelligence and regenerative medicine 33:23

1y ago33:23

33:23

Featuring: Mamatha Bhat MD, MSc, PhD, FRCPC Hepatologist & Co-Lead of Transplant AI initiative (TAI), Ajmera Transplant Program Scientist, Toronto General Hospital Research Institute, University Health Network Associate Professor, Division of Gastroenterology & Hepatology Director, Clinician-Scientist Training Program (CSTP), Department of Medicine…

1
Stuck in the sixties: The fight to fast-forward access to better cancer treatment 27:24

1+ y ago27:24

27:24

Featuring: Tom Whitehead, Co-Founder, Emily Whitehead Foundation. Courtney Horvath, PhD, Global Head of Strategy, Planning & Operations, Translational Medicine, Novartis. In this episode, we hear from two parents who supported their children through cancer treatments. Listeners will hear their unflinching accounts of what the children went through,…

1
CAR T therapies: Engineering immune cells to treat cancer 31:10

2y ago31:10

31:10

Featuring: Dr. Joerg Krueger, Medical Director, CAR T-Cell Program, The Hospital for Sick Children. Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine. Our guests discuss the future of CAR T-cell therapies, in a conversation covering autologous and allogeneic CAR T th…

1
Protecting the product of innovation: IP and commercialization in cell and gene therapies 34:23

2y ago34:23

34:23

Featuring: Mark Taylor, Director of Commercialization, University Health Network Dr. Irja Elliott Donaghue Technical & IP Specialist and Patent Agent, Notch Therapeutics In the past, there was little evidence to challenge the idea that if a therapeutics developer did not hold a patent, it did not have anything to commercialize. In this episode, gue…

1
Mentoring: making moves to maximize career growth 27:53

2y ago27:53

27:53

Featuring: Dr. Dolores Baksh, CEO of TAAV Biomanufacturing Solutions Susan Nichols, Chief Business Officer at ViroCell Biologics As the cell and gene therapy industry continues to grow rapidly, Dolores Baksh and Susan Nichols emphasize the importance of nurturing a new workforce equipped with the skills to pivot and persevere—crucial qualities for …

1
Unlocking the potential of induced pluripotent stem cells 27:31

2y ago27:31

27:31

Featuring: Dr. Lise Munsie, Vice President, iPSC Technology Platform, CCRM Dr. Stephen Sullivan, Programme Manager, Global Alliance for iPSC Therapies (GAiT) Drs. Lise Munsie and Stephen Sullivan explore some of the biggest challenges that will need to be addressed to unlock the potential of induced pluripotent stem cells (iPSCs), from regulatory i…

1
Training tomorrow’s talent: building the biomanufacturing workforce 23:05

2y ago23:05

23:05

Featuring: Dr. Qasim Rafiq, Associate Professor in Cell and Gene Therapy Bioprocess Engineering, University College London (UCL) Dr. Christine Allen, Vice-President, Ecosystem Development, adMare BioInnovations Drs. Christine Allen and Qasim Rafiq offer insight on how to train and retain tomorrow’s cell and gene therapy (CGT) workforce in a very co…

1
You get what you pay for 35:21

2+ y ago35:21

35:21

How will Canada’s health care system pay for cell and gene therapy cures? Featuring: Dr. Chris McCabe, CEO and Executive Director, Institute of Health Economics Robert Woolstencroft, Senior Director and Head, Market Access and Reimbursement, Gilead Sciences Canada Our guests tackle the complex question of how therapy developers working at the cutti…

1
A busy intersection: Ethics and policy in cell and gene therapies 35:25

2+ y ago35:25

35:25

Examining the role ethical considerations and regulatory frameworks will play in regenerative medicine’s future. Featuring: Prof. Bartha Maria Knoppers, Canada Research Chair in Law and Medicine, and Director of the Centre of Genomics and Policy, Faculty of Medicine, McGill University Siofradh McMahon, Director, Clinical Translation and Regulatory …

1
The Future’s Synthetic 25:23

3y ago25:23

25:23

Looking to the future of synthetic biology in cell and gene therapies. Featuring: Dr. George Church, Professor of Genetics, Harvard Medical School Dr. Peter Zandstra C.M., Director and Professor, School of Biomedical Engineering, University of British Columbia Hear from Drs. Church and Zandstra about the promise of the emerging synthetic biology fi…

1
Moving from A to B 31:10

3y ago31:10

31:10

Manufacturing and supply chain issues in cell and gene therapies. Featuring: Dr. Anthony Davies, Founder and CEO, Dark Horse Consulting Rob Jones, Vice President, Global Bioservices, Cryoport Systems It’s no secret that supply chain and manufacturing are crucial to the cell and gene therapy industry, but now the whole world seems to be paying atten…

1
Chaperoning innovation through the valley of death 26:32

3y ago26:32

26:32

The business of regenerative medicine and investment. Featuring: Dr. Cynthia Lavoie, President and Chief Investment Officer, CCRM Enterprises Geoff MacKay, President and CEO, AVROBIO Dr. Lavoie and Mr. MacKay share what brought them to regenerative medicine in the first place, why investors are bullish about the field, and which trends they have an…

1
The importance of educating the public about cell and gene therapies 24:43

3y ago24:43

24:43

How can the regenerative medicine community create broader societal awareness? Featuring: Dr. Janet Rossant, President and Scientific Director, Gairdner Foundation Dr. Phil Vanek, Chief Technology Officer, Gamma Biosciences Drs. Rossant and Vanek discuss public awareness of cell and gene therapies, the importance of improving it, and how confusing …

المدونة الصوتية تستحق الاستماع

Ccrm بودكاست

المدونة الصوتية تستحق الاستماع

1
Commercializing Living Therapies with CCRM

CCRM

1
Biomanufacturing redefined: The role of AI and robotics in producing cell and gene therapies 34:59

1
Expert insights for taking a cell or gene therapy company from vision to reality 26:25

1
Regulators' strategies for managing the surge in cell and gene therapies 27:35

1
How Creative Destruction Lab accelerates the advanced therapies industry 24:23

1
The synergy solution: How public-private partnerships advance regenerative medicine 34:43

1
Catalysts of change: Canada’s research hubs are shaping the future of biomanufacturing 33:24

1
From code to cure: Exploring the synergies of artificial intelligence and regenerative medicine 33:23

1
Stuck in the sixties: The fight to fast-forward access to better cancer treatment 27:24

1
CAR T therapies: Engineering immune cells to treat cancer 31:10

1
Protecting the product of innovation: IP and commercialization in cell and gene therapies 34:23

1
Mentoring: making moves to maximize career growth 27:53

1
Unlocking the potential of induced pluripotent stem cells 27:31

1
Training tomorrow’s talent: building the biomanufacturing workforce 23:05

1
You get what you pay for 35:21

1
A busy intersection: Ethics and policy in cell and gene therapies 35:25

1
The Future’s Synthetic 25:23

1
Moving from A to B 31:10

1
Chaperoning innovation through the valley of death 26:32

1
The importance of educating the public about cell and gene therapies 24:43

دليل مرجعي سريع